China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

 
• By Sten Stovall

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.

Success
EpimAb is using its platform to develop a pipeline of bispecific antibodies • Source: Shutterstock

More from Start-Ups & SMEs

More from Business